Why to choose Rispoval RS+Pi3 Intranasal?
Rispoval RS+Pi3 IntraNasal is a single dose at 9 days of age with protection against RSV as early as 14 days of age. Vaccine B3 - 2 dose vaccination course completed at 42 days of age with highest antibody immunity not achieved until day 56. Rispoval RS+Pi3 Intranasal provides proven RSV and Pi3 protection earlier and longer than vaccine B.
Learn more in following videos ...
Intranasal Administration |
|
Mode of Action |
-
Heifers that perform best in the First 60 Days of life
- Survive longer
- Produce more milk
=>Deliver more profit
The First 60 Days in the life of a replacement dairy heifer are key to maximise lifetime productivity.
- Growth during the First 60 Days of life is positively correlated with survivability to second lactation2
- Additional average daily gain (ADG) during the First 60 days = Additional milk yield in the first lactation3
- Priorities for future performance = Energy intake pre-weaning and colostrum management4
1. Early Growth & Survivability: (Bach 20112)
- Average Daily Gain (ADG) during the First 60 Days of life was linked with survivability to second lactation
- Heifers that reached second lactation grew more (0.8kg/d) between 12 and 65 days than those that did not (0.7kg/d)
- No effect was found between ADG after first breeding and survivability to second lactation
2. Early Growth & Milk Yield:( Bach 20123)
- For every additional 100g of ADG during the First 60 Days of life, about 225kg of additional milk yield in the first lactation can be expected.
(This is an average figure of 7 studies)
3. Priorities for The First 60 Days: (Soberon 20124)
- Energy intake pre-weaning along with colostrum management have the greatest impact on future performance
- Pre-weaning Average Daily Gain accounted for 22% of the variation in first-lactation milk yield
- Increased growth rate before weaning results ‘in some form of epigenetic programming that is yet to be understood, but has positive effects on lactation milk yield’
Heifers that perform best in the First 60 Days of life
- Survive longer
- Produce more milk
=>Deliver more profit
-
- As the number of respiratory cases a heifer experiences increases, her productive life diminishes: Heifers suffering more than 4 cases have an average of 100 days less productive life2
- Pneumonia in young dairy calves costs an average of €538per case at time of disease (treatment costs, time etc.)
- Pneumonia in dairy calves pre-weaning has been shown to reduce 1st lactation yield by 4%10 and to reduce 2nd lactation yield by 8%10
-
- Heifer rearing represents up to 20% of farm expenses1
- €1500 average cost to calve a heifer at 24 months1
- Age at first calving determines return on investment
Cows with a longer life and higher production =>Increased farm profit + More sustainable production
-
1.Moorepark data: Emer Kennedy & Laurence Shaloo 2011
2.Bach 2011 Associations between several aspects of heifer development and dairy cow survivability to second lactation
3.Bach 2012 Nourishing and managing the dam and postnatal calf for optimal lactation, reproduction, and immunity
4.Soberon 2012 Preweaning milk replacer intake and effects on long-term productivity of dairy calves
5.Wathes 2008: Factors influencing heifers survival and fertility
6.Meale2012: Strategies to reduce greenhouse gases from ruminant livestock
7.All Island Disease Surveillance 2014 8.Andrews 2000 CATTLE PRACTICE VOL 8 PART 2 Calf Pneumonia Costs
9.Van Der Fels-Klerx 2002 Effects of bovine respiratory disease on the productivity of dairy heifers quantified by experts
10.Morrison 2011 Calf management for lifetime Performance: Effect of pneumonia – pre-weaning
Summary of Product Characteristics: Full product licence here
Presentations: Single dose vial, 5 dose vial (10ml), 25 dose vial (50ml)
Dosage:2 ml by intranasal administration from 9 days of age
Withdrawal:0 days
Legal Category: POM (E)
VPA Number:10438/089/001
- Argentina
- Australia
- Austria
- Belgium
- Bolivia
- Brazil
- Bulgaria
- Canada
- Chile
- China
- Colombia
- Costa Rica
- Croatia
- Czech Republic
- Denmark
- Ecuador
- Egypt
- Estonia
- Ethiopia
- Finland
- France
- Germany
- Ghana
- Greece
- Hungary
- India
- Indonesia
- Ireland
- Israel
- Italy
- Japan
- Kenya
- Latvia
- Liberia
- Lithuania
- Malawi
- Malaysia
- Mauritius
- Mexico
- Morocco
- Mozambique
- Netherlands
- New Zealand
- Nigeria
- Paraguay
- Peru
- Philippines
- Poland
- Portugal
- Romania
- Russia
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- South Korea
- Spain
- Switzerland
- Taiwan
- Tanzania
- Thailand
- Turkey
- Uganda
- Ukraine
- United Kingdom
- United States
- Uruguay
- Vietnam
- Zambia
- Zimbabwe
You are now leaving the regional website to access another site in the group.
Regulatory constraints and medical practices vary across regions from market to market. Consequently, the information provided on the site in which you enter may not be suitable for use in your region.